Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poliovirus type 3 antigen (formaldehyde inactivated) is a purified, non-infectious viral component used to confer immunity against Type 3 poliovirus. It is most commonly derived from the Saukett strain, which is cultivated in cell lines such as Vero or primary monkey kidney cells. Following cultivation, the virus is concentrated, purified, and inactivated using formaldehyde (formalin), a process that destroys viral infectivity while maintaining the structural integrity of the D-antigen, the primary immunogenic site. This antigen is a critical constituent of the trivalent Inactivated Poliovirus Vaccine (IPV), originally developed by Jonas Salk, and is also included in various pediatric combination vaccines (e.g., DTaP-IPV-HepB-Hib). Upon administration, it stimulates the host's immune system to produce neutralizing antibodies that prevent the virus from infecting the central nervous system, thereby protecting against paralytic poliomyelitis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on poliovirus type 3 antigen (formaldehyde inactivated).